BDR Pharma on Monday said it has inked a licensing pact with the Defence Research and Development Organisation (DRDO) to manufacture, distribute, and market COVID-19 drug 2-Deoxy-D-Glucose (2-DG) in the country. BDR Pharma has inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.
Last month, the Drugs Controller General of India (DCGI) had approved the oral medication for emergency usage as adjuvant therapy in mild to severe COVID-19 patients.
“We are pleased to secure a license from the DRDO and add 2-Deoxy-D-Glucose to our COVID product offering. This arrangement aims to ensure that this drug reaches as many eligible Indian patients as possible who are suffering from the devastating pandemic.
Losing weight is a significant milestone, but for many, the bigger battle lies in keeping…
In recent months, a growing controversy has surfaced regarding the presence of heavy metals—specifically lead…
A new study published in Scientific Reports has shed light on the potential benefits of dietary…
Zinc is an essential mineral that plays a crucial role in maintaining overall health. Known…
A groundbreaking clinical trial, spearheaded by a team of Indian and international experts, has shed…
In an unprecedented discovery, scientists have uncovered a surprising connection between COVID-19 infections and the…